Investigating the essential roles of Ubiquitin-like molecules and the Ubiquitin Proteasome System

Research Project 2.
Proteasome activation to treat neurodegeneration.

Objectives

Our aim is to develop small-molecule proteasome activators. These are emerging as potentially powerful agents for the treatment of neurodegenerative diseases. A dozen of distinct small molecules have been identified recently at The Netherlands Cancer Institute (P4-NKI) and UbiQ has an exclusive licence for the further developments of these agents. From this set, several compounds will be chosen as lead compounds for a structure-activity relationship study – the aim is not only to enhance proteasome activation potency but also other pharmacological important factors (e.g. solubility in water).

Partner

NKI-AVL

Group

Huib Ovaa